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httpcense.Abstract Background: Environmental tobacco smoke (ETS) is the primary etiological factor of
lung cancer. However, only 10–15% of smokers develop lung cancer, suggesting genetic role in
modifying individual susceptibility to lung cancer. Antioxidant enzyme functional genetic polymor-
phisms should be considered.
Aim of the work: The present study aimed to evaluate the role of antioxidant enzyme activity and
genetic polymorphisms in modifying the susceptibility to lung cancer among individuals exposed to
ETS.
Subjects and methods: A total of 150 male subjects were divided into three groups: 50 lung cancer
patients, 50 chronic smokers and 50 passive smokers. Genotyping of mEH exon 3 (Tyr113Hist) and
exon 4 (Hist139Arg) polymorphisms was done by PCR–RFLP technique. MnSOD (Val16Ala)
polymorphism was detected by Real time-TaqMan assay. Erythrocyte MnSOD activity was
measured spectrophotometrically.
Results: ETS exposed individuals (both active and passive smokers) who carried His allele of
mEH exon3 have 2.9-folds increased risk of lung cancer (OR 2.9 P< 0.001). Also ETS exposed
carriers of Arg allele of mEH exon 4 have 2.1-folds higher risk to lung cancer (OR 2.1
P= 0.024). However no association between MnSOD Val16Ala polymorphism and lung cancer
was detected among ETS (OR 1.6 P= 0.147), although lung cancer group had signiﬁcantly lower
MnSOD activity than chronic or passive smokers groups (P= 0.03).
Conclusion: Exons 3 and 4 polymorphisms of the mEH gene may contribute to lung cancer sus-
ceptibility through disturbed antioxidant balance. However, this was not the case with MnSOD
Val16Ala SNP. Antioxidant enzymes may modulate the inﬂuence of ETS exposure on lung cancer
risk.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.3382517.
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Environmental tobacco smoke (ETS) refers to the exposure of
a non-smoker to the smoke produced from cigarettes con-
sumed by another person. It is also called second-hand smoke,
passive smoking or involuntary smoking [1]. Exposure to to-
bacco smoke, either by active or passive smoking, is the pri-
mary etiologic factor responsible for lung cancer. Long-term
tobacco smoke exposure was found to cause 80–90% of lung
cancers worldwide [2]. Although most of lung cancer patients
are smokers or ex-smokers, in fact many of them are also
non-smokers and only 10–15% of smokers may develop lung
cancer in their lifetime, suggesting that environmental factors
(mainly tobacco smoke) interact with multiple polymorphic
genes to inﬂuence cancer susceptibility [3,4].
Mild oxidative stress occurs on a daily basis and is a key
factor in maintaining homeostasis. However, strong, acute,
or chronic oxidative stress disrupts this delicate homeostasis
and causes oxidative damage to lipids, proteins and nucleic
acid molecules leading to increased vulnerability to malignant
diseases [5].
Microsomal epoxide hydrolase (mEH), a phase II meta-
bolic enzyme, catalyzes the hydrolysis of epoxides from poly-
cyclic aromatic hydrocarbons and aromatic amines of
cigarette smoke [6]. Although this hydrolysis is generally a
detoxiﬁcation reaction as less reactive and more water soluble
dihydrodioles are produced, in case of some hydrocarbons
such as benzo(a)pyrene, present in tobacco smoke, more
highly reactive and mutagenic compounds are generated. Thus
mEH exhibits a dual role of procarcinogen detoxiﬁcation and
activation depending on the substrate [7,8]. In the coding re-
gion of mEH gene, two common polymorphisms are charac-
terized within exons 3 and 4. In exon 3, a T > C transition
resulting in Tyr113His substitution, is associated with 40-
50% decrease in the in vitro activity of mEH, and thus this
allelic conversion has been referred to as the ‘‘slow’’ allele.
The second variant is characterized by an A > G transition
in exon 4 causing His139Arg substitution, and is associated
with 25% increase of enzyme activity. This allele has been
called the ‘‘fast’’ allele. The distance between exon 3 and exon
4 is 6696 base pairs [9].
Given the known differential effect of mEH alleles in the
detoxiﬁcation of procarcinogens, it has been proposed that
these polymorphisms may affect cancer risk [10].
A number of antioxidants enzymes are involved in the
scavenging of reactive oxygen species (ROS), including the
superoxide dismutase (SOD) family members (Mn, Cu and
ZnSOD). Theses enzymes catalyzes the dismutation of super-
oxide anion ðO2 Þ to form hydrogen peroxide (H2O2), which
is further detoxiﬁed to water by glutathione peroxidase [11].
MnSOD is the only SOD essential for life, and the major anti-
oxidant in the mitochondria. MnSOD precursor protein is syn-
thesized with a cleavable N-terminal mitochondrial targeting
sequence (MTS) which derives the mitochondrial import of
MnSOD from the cytoplasm. Genetic polymorphism at codon
16 of MnSOD/MTS leads to substitution of alanine (GCT) for
valine (GTT) T > C (Val 16 Ala, rs4880) [12]. This polymor-
phism was reported to be functional in affecting the transport
of the enzyme into mitochondria with the Ala variant account-
ing for more efﬁcient importation [13]. A number of molecular
studies have been conducted to examine the link betweenMnSOD Val 16 Ala and cancer susceptibility [14–16], but
the results remain inconsistent. The aim of the present study
is to evaluate the role of mEH and MnSOD enzyme activity
and genetic polymorphisms in modifying the susceptibility to
lung cancer among individuals exposed to ETS.
Patients and methods
This cross-sectional study was performed in the Chemical
Pathology Department in collaboration with the Chest Dis-
eases Department, Kasr Al Aini Faculty of Medicine, Cairo
University, from June 2011 until March 2013.
The study was conducted on 150 male subjects with their
age ranged between 35 and 70 years, divided into three groups
each of 50 subjects as follows: Group I: Lung cancer patients
diagnosed clinically, radiologically and conﬁrmed by histopa-
thological examination of bronchoscopic or CT guided biopsy.
Group II: Chronic smokers. They have been smoking for at
least 10 years with a minimum of 1 pack/day i.e. (smoking
index with a minimum of 10 pack/year). Group III: Healthy
passive smokers, with no medical history of lung disease (no
cough, expectoration or shortness of breath). All subjects were
asked about their age, chest symptoms, other co-morbidities,
smoking history to calculate smoking index (by multiplying
the number of cigarette packs smoked/day by the number of
years the person has smoked (pack/year) according to the
National Cancer Institute (USA) deﬁnition of pack/year [17].
Exclusion criteria
Subjects suffering from other co-morbidities which may lead to
oxidative stress such as diabetes, cardiac disorders, severe
infections, severe liver and kidney disease are excluded.
Specimen collection and storage
All subjects in this study were informed and verbal consents
were taken. Six ml venous blood was withdrawn from all sub-
jects and divided into 3 parts: (a) Two ml was collected in a
sterile EDTA vacutainer for DNA extraction. Samples were
kept frozen at 20 C till the time of analysis. (b) Two ml
was collected in EDTA containing tube for measurement of
erythrocyte MnSOD activity. (c) Two ml was collected on
plain tubes, left for 10 min to clot and then centrifuged at
3000 rpm for 5 min, to separate serum for routine laboratory
investigations (liver and kidney functions) for the exclusion
criteria.
DNA preparation
Extraction of genomic DNA from sterile EDTA anticoagulat-
ed blood samples was done using QIAamp DNA blood Mini
kit (Qiagen, Hilden, Germany) by silica-gel spin columns [18].
Analysis of mEH gene polymorphisms (exon 3 and exon 4)
using Polymerase chain reaction (PCR) followed by Restriction
Fragment Length Polymorphism (RFLP) analysis
The PCR-RFLP of extracted genomic DNA was performed as
described by Cheng et al. [18]. DNA ampliﬁcation was per-
formed in Gradient thermal cycler (Professional thermocycler,
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ing the thermal proﬁle to initial denaturation at 95 C for
10 min followed by 35 cycles of 30 s at 94 C, annealing
temperature of 55 C (exon 3) or 62 C (exon4) for 30 s and
extension at 72 C for 30 s. Speciﬁc Oligonucleotide primers
were synthesized by Fermentas (Fermentas UAB, V.
Graiciuno 8, Lithuania) as follows: exon 3 sense: 50-GAT-
CGATAAGTTCCGTTTCACC-3; Anti-sense 50-ATCCT-
TAGTCTTGAAG TGAGGAT-30 (engineered base change,
G to A, underlined); exon 4 sense: 50-ACATCCACTTCATCC
ACGT-30; Anti-sense: 50-ATGCCTCTGAGAAGCCAT-30.
Each PCR product was digested with Eco RV (exon 3) or
Rsa I (exon 4) (Fermentas, Thermo Fisher scientiﬁc, USA),
separated by electrophoresis on 3% agarose gel, stained with
ethidium bromide and transilluminated with ultraviolet light.
The exon 3 wild-type allele was expected to yield 140- and
22-base-pair (bp) fragments, whereas the variant allele re-
mained an uncleaved 162-bp fragment (Fig. 1). Conversely,
the exon 4 wild-type allele remained an uncleaved 210-bp frag-
ment, whereas the variant allele was expected to yield 164- and
46-bp fragments (Fig. 2). According to the report of Smith and
Harrison [19], the four groups of putative mEH activity pheno-
types were classiﬁed as follows: normal (no mutation or het-
erozygous for both exon 3 and 4), fast (at least one fast exon
4 allele and no exon 3 mutations), slow (one slow exon 3 al-
lele), and very slow (two exon 3 slow alleles).
Analysis of MnSOD (Val 16 Ala) polymorphism by Real time
PCR technique using TaqMan SNP genotyping assay [20]
Real-time PCR allelic discrimination was designed using Taq-
Man SNP Genotyping Assays (Applied Biosystems) and
performed on Step One Real Time PCR System (Applied Bio-
systems, Foster City, CA), using the ﬂuorogenic 50nuclease with
TaqMan minor groove binder (MGB) probes to deﬁne the
MnSOD gene SNP c.47T>C, Val16Ala (rs 4880), assay ID:
C_8709053_10. The wild type TaqManMGB probe was VIC la-
beled (Allele 1) and themutant probewasFAMlabeled (Allele 2).
The ﬁnal volume of each reaction was 25ul, consisting of
12.5 ul TaqMan Universal PCR Master Mix (2X) which con-
tained AmpliTaq-Gold DNA polymerase, 1.25ul assay mix
(20X) contained primers and probes, 5ul genomic DNA, and
6.25ul nuclease free water. Negative control (no DNAFigure 1 mEH exon 3 (Tyr 113 His) identiﬁed bands after transillum
and 2: heterozygous Tyr/His, lanes 3 and 4: homozygous mutant His/
was too small to be detected).template) was run to ensure that there was no ampliﬁcation
of contaminating DNA. The ampliﬁcation reactions were car-
ried out with initial hold step at 95 C for 10 min for activation
of AmpliTaq-Gold DNA polymerase followed by 40 cycles of
three-step PCR: denaturation at 92 C for 15 s, annealing at
60 C for 30 s and extension at 60 C for 30 s. The ﬂuorescence
signal increases when the probe with the exact sequence match
binds to the single stranded template DNA and is digested by
the 50nuclease activity of AmpliTaq-Gold DNA polymerase.
Digestion of the probe releases the ﬂuorescent reporter dye
(either FAM or VIC) from the quencher dye.
Determination of erythrocyte MnSOD enzyme activity [21]
MnSOD catalytic activity was determined with RANSOD kit
(Randox Labs, Crumlin, UK) according to the manufacturer’s
protocol. In brief, SOD catalytic activity wasmeasured by utiliz-
ing tetrazolium salt, which produces red formazan dye upon
reduction with a superoxide anion ðO2 Þ produced by xanthine
and xanthine oxidase. MnSOD activity is then measured by
the degree of inhibition of this reaction. One unit of SOD is that
which causes a 50% inhibition of the rate of reduction of tetrazo-
lium salt. The test was performed on spectrophotometer BTA
350 (Biosystems S.A., Barcelona, Spain) by recording the in-
crease in absorbance at 505 nm at 37 C against air blank. Per-
centage inhibition of sample was used to obtain units of SOD
from standard curve.MnSODactivitywas expressed asUnit/ml.
Statistical analysis
The SPSS computer software, version 10.0 (Chicago, IL, USA)
was used for data analysis.
Quantitative data were presented as mean ± SD for nor-
mally distributed data. For comparison of the groups’ means,
Student’s t-test and ANOVA were used followed by Post Hoc
test. Correlation between quantitative variables was done
using Pearson’s correlation coefﬁcient (r). Qualitative data
were expressed as frequency and percentage. Associations be-
tween categorical and dichotomous variables were tested using
Pearson’s chi-squared test or Fisher’s exact test. The odds ratio
(ORs) and corresponding 95% conﬁdence intervals (CIs) were
estimated. All tests were two tailed and considered signiﬁcant
at P< 0.05.ination by UV transilluminator: (L) DNA 100 bp ladder, lanes 1
His, lanes 5 and 6: wild genotype Tyr/Tyr. (N.B.: The 22 bp band
Figure 2 mEPHX exon 4 (His 139 Arg) identiﬁed bands after transillumination by UV transilluminator: (L): DNA ladder (100 bp), lanes
1 and 4: wild genotype (His/His), lane 2: homozygous mutant Arg /Arg, lane 3: heterozygous genotype (His/Arg). (N.B.: The 46 bp band
was too small to be detected).
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The age, smoking index, enzyme genotype distribution and
activity are presented in Table 1. mEH gene and exon 3
polymorphism, showed a signiﬁcant difference in the genotype
and allele distribution among the three groups. HomozygousTable 1 Principle characteristics, antioxidant enzymes genotypes fr
Gene Lung cancer
(n= 50)
C
(
Age (years) 51 ± 11 4
Smoking index (Pack/year) 29.5 ± 22.4 3
mEH (exon 3) genotype
Tyr/Tyr Frequency (%) 28 (56%) 3
Tyr/His 14 (28%) 1
His/His 4
Allele 8 (16%)
Tyr 70 (70%) 7
His 30 (30%) 2
mEH (exon 4) genotype
His/Hi Frequency (%) 36 (72%) 4
His/Arg 8 (16%) 6
Arg/Arg 6 (12%) 3
Allele
His 80 (80%) 8
Arg 20 (20%) 1
MnSOD (Val 16Ala) genotype
Val/Val Frequency (%) 17 (34%) 2
Val/Ala 27 (54%) 1
Ala/Ala 6 (12%) 8
Allele
Val 61 (61%) 6
Ala 39 (39%) 3
Predicted mEH activity a b
Normal n (%) 19 (38%) 2
Slow 12 (24%) 1
Very slow 7 (14%) 2
Fast 12 (24%) 6
MnSOD activity (mean ± SD) 2.3 ± 1.2 2
(U/ml) A A
Groups bearing same initials are statistically indifferent at P value 0.05.mutant His/His genotype was absent among the passive
smokers and presented in 16% of lung cancer group. While
homozygous wild genotype Tyr/Tyr showed the highest fre-
quency (90%) among the passive smoker group and was lowest
among lung cancer group (56%) (P = 0.002). However exon 4
polymorphism of mEH gene and MnSOD Val16Ala showedequency and activity levels among the studied groups.
hronic smokers
n= 50)
Passive smokers
(n= 50)
P-value
7 ± 9 45 ± 10
5 ± 16.4 – –
3 (66%) 45 (90%)
3 (26%) 5 (10%) 0.002
(8%) 0 (0%)
9 (79%) 95 (95%) <0.001
1 (21%) 5 (5%)
1 (82%) 43 (86%)
(12%) 5 (10%) 0.441
(6%) 2 (4%)
8 (88%) 91 (91%) 0.065
2(12%) 9 (9%)
3 (46%) 21 (42%)
9 (38%) 25 (50%) 0.446
(16%) 4 (8%)
5 (65%) 67 (67%) 0.666
5 (35%) 33 (33%)
c
9 (58%) 38 (76%)
3 (26%) 5 (10%) 0.002
(4%) 0 (0%)
(12%) 7 (14%)
.2 ± 1.1 2.9 ± 1.0 0.03
b
Table 3 Relation between MnSOD enzyme activity and
genotypes.
MnSOD Genotype MnSOD activity
(U/ml) (mean ± SD)
P-value
Val/Val (n= 61) 3.2 ± 0.8 a
Val/Ala (n= 71) 2.3 ± 0.9 b <0.001
Ala/Ala (n= 18) 0.7 ± 0.4 c
Groups bearing same initials are statistically indifferent at P value
0.05.
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among groups (Table 1).
Predicted mEH enzyme activity among the studied groups
showed that the prevalence of normal activity increased expo-
nentially from lung cancer group to passive smokers, in con-
trast the frequencies of the very slow and the fast activities
were highest among lung cancer group, this difference was sig-
niﬁcant (P= 0.002), while comparison between mean values
of MnSOD activity level showed that the highest activity was
recorded among the passive smokers and the lowest activity
was recorded among lung cancer group, this difference was sig-
niﬁcant (P= 0.03) (Table 1).
A signiﬁcant association between lung cancer risk with
mEH exon 3 and 4 polymorphisms was revealed. Chronic
and passive smokers carrying the mutant His allele of exon 3
polymorphism have 2.9 folds increased risk of developing lung
cancer than carriers of the wild Tyr allele. Also those carrying
the mutant Arg allele of exon 4 have 2.1 folds higher risk ofCig sm
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Figure 3 Scatter diagram showing correlation between cigar
Table 2 Odds Ratios (OR) for the (mEH) gene po
versus chronic and passive smokers groups together.
Group Lung cancer Chro
smok
Frequency (%)
mEH (exon 3)
Tyr/Tyr 28 (56%) 78 (78
Tyr/His and His/His 22 (44%) 22 (22
Tyr 70 (70%) 174 (8
His 30 (30%) 26 (13
mEH (exon 4)
His/His 36 (72%) 84 (84
His/Arg and Arg/Arg 14 (28%) 16 (16
His 80 (80%) 179 (8
Arg 20 (20%) 21 (10
MnSOD (Val 16 Ala)
Val/Val 17 (34%) 44 (44
Val/Ala and Ala/Ala 27 (54%) 44 (44
Val 61 (61%) 132 (6
Ala 39 (39%) 68 (34lung cancer than carrier of the wild His allele. However no sig-
niﬁcant association was found between lung cancer risk and
MnSOD genotypes or alleles (Table 2).
Correlation between cigarette smoking index (pack/years)
and MnSOD enzyme activity (U/ml) showed statistically sig-
niﬁcant negative correlation (r= 0.33, P< 0.001) (Fig. 3).oking index
60.0050.0040.0030.00
ette smoking index and MnSOD enzyme activity (U/ml).
lymorphisms and MnSOD in lung cancer group
nic and Passive
ers
OR (95%CI) P-value
%)
%) 2.1 (1.1–4.5) 0.046
7%)
%) 2.9 (1.6–5.2) <0.001
%)
%) 2.0 (1.1–4.6) 0.049
9.5%)
.5%) 2.1 (1.1–4.2) 0.024
%)
%) 1.6 (0.7–3.7) 0.147
6%)
%) 1.2 (0.8–2.0) 0.234
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and Val 16 Ala genotype, comparison of the mean values of
MnSOD activity across the three MnSOD genotypes showed
that the highest activity was recorded among the homozygous
wild genotype (Val/Val) and the lowest activity was found
among homozygous mutant genotype (Ala/Ala). This differ-
ence was signiﬁcant (P< 0.001) (Table 3).
Discussion
Genetic differences in metabolic activation or detoxiﬁcation of
environmental carcinogen, like polycyclic aromatic hydrocar-
bons present in tobacco smoke, may partially explain host sus-
ceptibility to smoke induced cancers [21].
In this study, ETS exposed individuals (both active and
passive smokers) who carry the mutant His allele of mEH exon
3 polymorphism have 2.9 folds increased risk of developing
lung cancer (P< 0.001).
In agreement, Tilak et al. [22] in Indian population and
Erkisi et al. [23] have also revealed that smokers with His/
His genotype have signiﬁcantly greater risk of lung cancer.
On the other hand, exon 3 genotypes of mEH have been linked
to a decreased lung cancer risk in several studies [24–26]. A
meta-analysis by Wang et al. [4] found that pooled results of
the Caucasians subgroup revealed that mEH exon 3 polymor-
phism is protective against lung cancer. However, in the Asians
subgroup analysis, the pooled results showed an associated
with increased risk of lung cancer. This suggested that there
is an obvious race-speciﬁc effect.
In the present study, passive and active smokers who car-
ried the Arg variant allele of mEH exon 4, polymorphism (fast
allele) have 2.1 fold increased risk of developing lung cancer
(P= 0.024). Similarly, Li et al. [26] and Liu et al. [27] showed
that fast allele Arg was signiﬁcantly associated with increased
risk of lung cancer. These ﬁndings could be explained by the
role of mEH enzyme in transforming epoxide intermediates
into more reactive carcinogenic metabolites, which emphasizes
that high mEH activity is not protective in smokers with a high
cumulative dose of carcinogens derived from smoking [28].
In the present study, it was noticed that the fast and very
slow predicted mEH activity showed the highest frequency in
lung cancer group in comparison to chronic smokers and pas-
sive smokers (P= 0.002). It has been shown that cigarette
smoking can signiﬁcantly induce the activity of mEH [29].
Hydrocarbons such as benzo(a)pyrene are activated by mEH
into reactive intermediates and higher mEH activity leads to
higher concentrations of DNA adducts in the body compared
with very slow activity of mEH [28], thus putative high mEH
activity may have a harmful effect. Either low or high mEH
metabolizers should be seriously considered for their ability
to simultaneously decrease and increase the bioactivation of
speciﬁc compounds [30]. The most commonly studied poly-
morphism of MnSOD is Val16Ala on mitochondrial target se-
quence [12]. However, the speciﬁc role of the Val16Ala SNP in
cancer development was controversial.
In the current study, there was no signiﬁcant difference in
the MnSOD Val16Ala polymorphic genotypes or allele distri-
bution among groups. Therefore, no signiﬁcant association be-
tween MnSOD Val16Ala polymorphism and lung cancer
susceptibility was detected (OR: 1.2, P= 0.234).In agreement, previous studies conﬁrmed no association
existing between MnSOD (Val16Ala) polymorphisms and risk
of lung cancer [31,32]. However, since it was accepted that
MnSOD constitutes a ﬁrst-line defense against reactive oxygen
species (ROS), it would be a premature conclusion to remark
that this polymorphism has no role in lung cancer develop-
ment. MnSOD Val16Ala polymorphism could not be linked
to cancer risk alone. Rather, it has been proposed as low
penetrance allele. However combination with other polymor-
phisms in linkage disequilibrium that up-regulate and
down-regulate gene function, may be related to cancer risk
[33]. Another point to be considered is that some polymor-
phisms might be associated with cancer risk for some ethnic
communities only not for other ones.
In the current study, the MnSOD activity among lung can-
cer patients was signiﬁcantly lower than in chronic or passive
smokers (P= 0.03).
This was in accordance to many studies [16,31,34–36], in
which the MnSOD activity in the lung cancer was lower than
controls. The low activity of MnSOD in erythrocytes may be
caused, at least in part, by oxidant damage to the protein
MnSOD [16]. Another plausible explanation is due to in-
creased utilization to scavenge free radicals [35] or sequestra-
tion by tumor cells [36]. These ﬁndings suggest that the
lower levels of erythrocyte MnSOD activity in patients with
lung cancer are likely the consequence of the disease process
rather than a predisposing event in patients. This can explain
the signiﬁcant negative correlation that we found between cig-
arette smoking index (pack/year) and MnSOD enzyme activity
(U/ml), thus, the extent of cigarette smoking could potentially
affect MnSOD activity [11].
In agreement with the present study, Jain et al. [37] and
Gavali et al. [38] have all found that erythrocyte MnSOD
was signiﬁcantly lower in cigarette smokers as compared to
non-smokers.
Although mEH and Mn-SOD enzymes are considered to be
in the ﬁrst line of defense against oxidative stress, other en-
zymes such as catalase, glutathione peroxidase and glutathione
reductase have major contribution in protecting cells from oxi-
dative stress [39]. Hence, it can be expected that only a proper
balance between the activities of these enzymes collectively can
protect cells from detrimental effects of oxidative stress.
To sum up, this study indicated that mEH exon
3(Tyr113Hist) and exon 4 (Hist139Arg) polymorphisms that
alter enzyme activity might contribute to lung cancer suscepti-
bility among ETS exposed individuals through disturbed anti-
oxidant balance. However, MnSOD Val16Ala polymorphism
might not be associated with lung cancer risk, although
MnSOD enzyme activity was signiﬁcantly affected by smoking
through its consumption in attacking ROS, leading to dysfunc-
tion of antioxidant defense mechanisms, yet it cannot be dis-
tinguished whether this decrease in activity is a risk factor
for lung cancer or not. Governments should adopt and imple-
ment comprehensive smoke-free legislations in all public places
and workplaces to protect all people from exposure to tobacco
smoke.
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